Jeffrey W Kaliebe, David K Murdock
Journal: WMJ : official publication of the State Medical Society of Wisconsin 2009;108(7):373-5
PMID: 19886587
BACKGROUND
Ranolazine is a new anti-anginal agent that inhibits abnormal late sodium currents, indirectly causing a decrease in diastolic cardiomyocyte calcium levels. This produces an energy-sparing effect and stabilizes cardiac membranes. Ranolazine has been shown to be a potent inhibitor of triggered activity in the experimental setting.
METHODS
This case report describes the dramatic antiarrhythmic effects of ranolazine in a patient with highly symptomatic complex ventricular ectopy, including non-sustained ventricular tachycardia (NSVT). Cardiac ischemia and left ventricular systolic dysfunction were ruled out by cardiac catheterization. After failing standard treatment, we initiated ranolazine therapy.
RESULTS
Ranolazine was effective in suppressing ectopic ventricular activity and completely suppressed NSVT.
CONCLUSIONS
Further research on the anti-arrhythmic properties of ranolazine in the clinical setting is needed.
© Copyright 2026, Nutrition Evidence
We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.